Portosystemic shunt (PSS) — also known as a liver shunt — in dogs is a medical condition that affects the normal flow of blood through the liver. Under typical circumstances, blood from the intestine, ...

Shifamed portfolio company Adona Medical has raised $33.5m in a Series C financing round for supporting the next stage of product development and initiating clinical use of its interatrial shunt and ...

For babies born with a certain heart defect, implantation of a "shunt" is essential to their survival. A new type of shunt can be expanded using light after it's been implanted, potentially ...

10 patients enrolled with 100% implantation success Adona's adjustable interatrial shunt is designed so it can be modified post-implantation to provide a more adaptive and personalized lifetime ...

NEWARK, Del, Feb. 20, 2024 (GLOBE NEWSWIRE) -- According to Future Market Insights’ latest industry analysis, the Hydrocephalus Shunt Market size is estimated to be around US$ 546.09 million in 2024.

44% reduction in total heart failure event rate and ongoing improvements in quality of life in responder group patients implanted with shunt REDUCE LAP-HF II is the world's first phase III trial to ...

TEWKSBURY, Mass., May 22, 2023 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced two-year results from its REDUCE LAP-HF II ...

LOS GATOS, Calif., Oct. 27, 2024 /PRNewswire/ -- Adona Medical, a Shifamed portfolio company that aims to deliver advanced solutions for heart failure, announced today the successful first-in-human ...

HINGHAM, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Having successfully concluded an independent in-vitro laboratory study and published the positive results earlier this year, the operational ...